The U.S. Food and Drug Administration sent a warning letter to MSO Curaleaf about making unproven claims that CBD can treat diseases such as Alzheimer’s.
- It was the first such letter the agency has sent to a multi-state operator. The company said it intends to remain compliant.
- “Among MSOs, Curaleaf has made the largest push into CBD – with a full “Curaleaf Hemp” line,” a Wall Street analyst said. “And the CVS partnership brought them a lot of attention…They’re a good company to make an example of “
- Curaleaf, the most valuable U.S. cannabis company, saw its stock drop on the news.